<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02639221</url>
  </required_header>
  <id_info>
    <org_study_id>PXT-CL15-001</org_study_id>
    <nct_id>NCT02639221</nct_id>
  </id_info>
  <brief_title>A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects</brief_title>
  <official_title>PXT002331 A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prexton Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prexton Therapeutics</source>
  <brief_summary>
    <textblock>
      The principal aim of this study is to obtain safety and tolerability data when PXT002331 is
      administered orally as single and multiple doses to healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Serious Adverse Events</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of clinically relevant signs or symptoms</measure>
    <time_frame>16 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>PXT002331</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PXT002331</intervention_name>
    <arm_group_label>PXT002331</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects will be; 1.1. males or females of non childbearing potential 1.2. For
             females, non childbearing potential is defined as follows:

               -  permanently sterile following hysterectomy, bilateral salpingectomy, bilateral
                  oophorectomy, or confirmed tubal occlusion (not tubal ligation)

               -  postmenopausal, defined as at least 1 year post cessation of menses (without an
                  alternative medical cause) 1.3. of any ethnic origin 1.4. between 18 and 60 years
                  of age, inclusive

          2. Subjects will have a 2.1. body mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2,
             inclusive 2.2. body weight between 50 kg and 100 kg, inclusive

          3. Subjects will be in good health, as determined by; 3.1. medical history 3.2. physical
             examination 3.3. vital signs assessment 3.4. 12 lead ECG and 24 hour Holter Monitoring
             3.5. clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is
             not acceptable)

          4. Subjects will have given their written informed consent to participate in the study
             and to abide by the study restrictions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>United Kingdom</name>
      <address>
        <city>United Kingdom</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2015</study_first_submitted>
  <study_first_submitted_qc>December 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2015</study_first_posted>
  <last_update_submitted>September 27, 2016</last_update_submitted>
  <last_update_submitted_qc>September 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

